Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics(US:MCRB) Globenewswire·2025-07-22 11:01About Seres Therapeutics Carlo Tanzi, Ph.D. Kendall Investor Relations ctanzi@kendallir.com Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received B ...